Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRALZINE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Essential hypertension (off-label),Hypertensive crisis (off-label)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Oral: 50-100 mg twice daily; maximum 200 mg/day.
250 mg orally twice daily
Terminal elimination half-life is 2-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily hepatic via N-acetyltransferase (NAT2); exhibits polymorphic acetylation. Metabolites include hydralazine pyruvate hydrazone and other hydrazone derivatives.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal (70-90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <10%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
85-90%, primarily to albumin.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
1.5-2.0 L/kg; indicates extensive tissue distribution, exceeding total body water.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 30-50% due to first-pass metabolism.
70-90% (oral); 100% (IV).
GFR 10-50 m L/min: 50 mg twice daily; GFR <10 m L/min: 50 mg once daily.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
1-2 mg/kg/day divided every 12 hours; maximum 5 mg/kg/day.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 25 mg twice daily; titrate slowly to avoid hypotension.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May induce a lupus-like syndrome, especially in slow acetylators; monitor for symptoms such as arthralgia, fever, and rash.,May cause drug-induced autoimmune hepatitis.,Can precipitate angina or myocardial infarction in patients with coronary artery disease.,Risk of hypotension and reflex tachycardia.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to hydralazine or components,Coronary artery disease (relative contraindication due to risk of myocardial ischemia),Mitral valve rheumatic heart disease (relative),Idiopathic lupus erythematosus
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
DRALZINE should be taken with or without food, but consistent timing is recommended. High-tyramine foods (e.g., aged cheeses, cured meats, fermented products) may increase the risk of hypertensive crisis in patients also taking MAOIs; however, interactions with food are otherwise minimal. Avoid large, high-fat meals as they may affect absorption.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fetal hypotension, adverse fetal heart rate patterns, and neonatal adverse effects (hypotension, tachycardia, fluid retention).
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Compatible with breastfeeding. M/P ratio not established; drug appears in breast milk in low amounts (<1% maternal dose). No reported adverse effects in infants.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No specific dose adjustments required based on pharmacokinetic changes in pregnancy. However, because of increased blood volume, higher doses may be needed to achieve same antihypertensive effect; titrate to target blood pressure.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
DRALZINE (hydralazine) is a direct-acting vasodilator used primarily for hypertension, especially in pregnancy (pre-eclampsia). It can cause a drug-induced lupus-like syndrome, especially in slow acetylators; monitor for arthralgias, rash, and positive ANA. Tachycardia is a common reflex response; often co-administered with a beta-blocker. Avoid in patients with coronary artery disease, high-output heart failure, or mitral valve rheumatic heart disease.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not skip doses or double up.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly and avoid sudden position changes.,Report any joint pain, rash, fever, or chest pain to your healthcare provider immediately.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,Do not stop taking this medication abruptly; sudden withdrawal can cause a rapid increase in blood pressure.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRALZINE vs ALDOCLOR-250, answered by our medical review team.
DRALZINE is a Antihypertensive that works by Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRALZINE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRALZINE is: Oral: 50-100 mg twice daily; maximum 200 mg/day.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRALZINE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRALZINE is classified as Category C. First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fet. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.